Project Grant R43CA291510
Award Date 8/5/25
Completion Date 7/31/26
Dollars Obligated $393K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Cancer Institute (NCI) has awarded a $727,904 Cooperative Agreement to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, under the Cancer Biology Research program (CFDA 93.396). The purpose of this 23-month award, with a start date of August 11, 2025, is to engineer probiotic bacteria (E. coli Nissle 1917) to identify precancerous lesions, characterize novel stage-specific immune targets, and design immunomodulatory...
- This $2,864,671 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Regents of the University of Michigan is focused on developing a novel strategy to enzymatically inhibit colibactin, a procarcinogenic metabolite from enteric bacteria associated with colorectal cancer (CRC). The objectives are to: (1) create engineered microbes that can deliver the colibactin inactivation protein ClbS to safely and effectively neutralize colibactin in the gut,...
- This $627,422 Project Grant award from the National Cancer Institute under the Cancer Treatment Research (CFDA 93.395) program supports research by the Regents of the University of Michigan to engineer commensal bacteria that can neutralize the colibactin genotoxin produced by certain gut bacteria associated with increased colorectal cancer risk. The key products and services to be delivered under this 5-year grant include: 1) Further optimization of the surface display of the anti-toxin...
- The federal Project Grant award of $697,763 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by The University of Texas MD Anderson Cancer Center to decipher the critical determinants of how the Fusobacterium nucleatum (FN) bacteria colonizes the colorectal cancer (CRC) tumor microenvironment and contributes to disease progression. The project aims to gain mechanistic insights into how this oral bacteria homes to and persists within the CRC tumor, as...
- This Project Grant award of $600,499.00 from the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), supports research conducted by The Trustees of Columbia University in the City of New York (Health Sciences Division) to investigate the role of the Fusobacterium nucleatum (FN) bacterium and the Annexin A1 (ANXA1) protein as potential biomarkers in colorectal cancer oncogenesis. The key objectives of this 5-year project are to: (I) mechanistically investigate...
- This federal Project Grant award of $606,839.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to identify gut microbiota that actively deplete intestinal amino acids and evaluate how they affect the tumor microenvironment and cancer progression. The primary awardee is Weill Medical College of Cornell University, a leading academic medical institution with expertise in biomedical research and translational science. The project aims to...
- This $248,998 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research by The General Hospital Corporation (Massachusetts General Hospital) to identify gut microbial and metabolomic biomarkers that link the consumption of ultra-processed foods to colorectal cancer risk. The research will leverage multi-omics data from large prospective cohorts and integrate a medically tailored meal intervention into the oncology care of colorectal...
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), provides $400,000.00 to Onconaut Therapeutics Inc. to develop novel combination therapies for the treatment of colorectal cancer. The project aims to evaluate the efficacy of combining FOLFIRI chemotherapy with CHD1L inhibitors (OTI-600 series), which have demonstrated antitumor activity as single agents and potential synergistic effects when combined with...
- This $1,355,273 Project Grant was awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to the Regents of the University of Michigan. The grant funds the development of two complementary approaches to inhibit the production of the bacterial metabolite colibactin, which has been linked to colorectal cancer and microbiome dysbiosis. The first approach involves enzymatic inactivation of colibactin through...
- The National Science Foundation (NSF) awarded a $353,843 Project Grant under CFDA Program 47.041 (Engineering) to the University of Washington to develop a unique biosensing system in E. coli bacteria to recognize extracellular cancer antigens and respond with a toxic, immunostimulatory payload. This 3-year project from March 2025 to February 2028 aims to create programmable and dynamically-responsive bacterial therapeutics as a low-cost alternative to engineered human T cell therapies for...